Class / Patent application number | Description | Number of patent applications / Date published |
436064000 | CANCER | 23 |
20080213907 | Protein markers for the diagnosis and prognosis of ovarian and breast cancer - Plasma samples of ovarian and breast cancer patients were used to search for markers of cancer, using two-dimensional gel electrophoresis and MALDI TOF mass spectrometry. Truncated forms of cytosolic serine hydroxymethyl transferase (cSHMT), T-box transcription factor 3 (Tbx3) and utrophin were aberrantly expressed in samples from cancer patients, as compared to samples from noncancer cases. Aberrant expression of proteins was validated by immunoblotting of plasma samples with specific antibodies to cSHMT, Tbx3 and utrophin. A cohort of 79 breast and 39 ovarian cancer patients, and 31 individuals who were either healthy or had noncancerous conditions was studied. We observed increased expression of truncated cSHMT, Tbx3 and utrophin in plasma samples obtained from patients at early stages of disease. The results indicate that cSHMT, Tbx3, utrophin and truncated forms thereof can be used as components of multiparameter monitoring of ovarian and breast cancer. | 09-04-2008 |
20080254547 | SUPRACOLONIC AERODIGESTIVE NEOPLASM DETECTION - The invention provides methods and materials for detecting supracolonic aerodigestive premalignant and malignant neoplasms. Specifically, the invention provides methods and materials for determining whether a stool sample from a mammal contains a neoplasm-specific marker from a neoplasm located in the supracolonic aerodigestive tissue of a mammal. | 10-16-2008 |
20080293147 | Method of Detecting Structural Change in Target Sugar Chain - A method of easily and efficiently detecting any structural change in a target sugar chain that can be present as a first or a second sugar chain depending on the structural change. In the method, the target sugar chain is mixed with a first to an n | 11-27-2008 |
20080318324 | Biochip for High-Throughput Screening of Circulating Tumor Cells - Embodiments in accordance with the present invention relate to the use of effusive filtration to segregate tumor cells from a sample of bodily fluid. In one embodiment, fluid containing a cell is flowed down a channel having a filtration medium present along at least one side wall. The tumor cell is captured when the fluid passes through the filtration medium. Accumulated pressure on the captured tumor cell is reduced by allowing the fluid that has passed through the filtration medium to re-enter the channel. In a particular embodiment, the filtration medium may comprise side wall apertures having a width smaller than that of the cell, with downstream apertures allowing re-entry of the fluid into the channel. | 12-25-2008 |
20090170208 | Biomarkers for ovarian cancer - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, it has been found that the biomarkers set forth in Table 1 are biomarkers for ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry. | 07-02-2009 |
20100203644 | DIAGNOSTIC TEST FOR THE DETECTION OF EARLY STAGE LIVER CANCER - The invention provides methods and kits to detect early stage hepatocellular carcinoma or a change in the gradation of hepatocellular carcinoma in mammals. The diagnostic marker is based on the profiling and identification of diagnostic carbohydrates present in a body fluid such as blood serum. | 08-12-2010 |
20100279419 | DETECTION OF SALIVA PROTEINS MODULATED SECONDARY TO DUCTAL CARCINOMA IN SITU OF THE BREAST - A method of differentiating among the presence of ductal carcinoma in situ in the breast, benign fibroadenoma of the breast, and non-cancerous breast tissue in a subject is disclosed. The method comprises: measuring the concentration of at least one protein biomarker selected from a group of forty-nine differentially expressed proteins in the saliva of persons with DCIS, or benign fibroadenoma, or in persons who are cancer-free. The resulting test data is compared to a reference panel. From the comparison the presence in the subject of either ductal carcinoma in situ of the breast, or benign fibroadenoma of the breast is determined. | 11-04-2010 |
20100291689 | Lanthanide Complexes as Fluorescent Indicators for Neutral Sugars and Cancer Diagnosis - A group of water-soluble salophene-lanthanide complexes and other salophene-metal complexes are useful for purposes including: (i) detecting neutral carbohydrates at physiologically-relevant pH, (ii) the selective detection of gangliosides, and (iii) the selective detection of lysophosphatidic acid (LPA) in the presence of phosphatidic acid. The selective detection of LPA is useful in diagnosing ovarian and other cancers. | 11-18-2010 |
20100291690 | METHODS FOR DETECTING OR MONITORING CANCER USING LPC AS A MARKER - A method of detecting a cancer, such as ovarian cancer, in a test subject including (a) determining the amount of a lysophosphatidyl choline in a sample of a bodily fluid taken from the test subject, and (b) comparing the amount of the lysophosphatidyl choline in the sample of the bodily fluid taken from the test subject to a range of amounts of lysophosphatidyl choline found in samples of the bodily fluid taken from a group of normal subjects of the same species as the test subject and lacking the cancer, such as ovarian cancer, whereby a change in the amount of the lysophosphatidyl choline in the sample of the bodily fluid taken from the test subject indicates the presence of the cancer, such as ovarian cancer. | 11-18-2010 |
20110027894 | BIOMARKERS FOR DETECTION OF EARLY- AND LATE-STAGE ENDOMETRIAL CANCER - Biomarker proteins that can be used in the diagnosis of early-stage endometrial cancer are described. Methods of screening for endometrial cancer, as well as methods of detecting and monitoring the status of endometrial cancer are provided. The biomarkers can be used to detect a variety of endometrial cancers, including endometroid carcinoma, clear cell carcinoma and serous carcinoma. | 02-03-2011 |
20110053278 | SYSTEMS AND METHODS FOR ENHANCING FLUORESCENT DETECTION OF TARGET MOLECULES IN A TEST SAMPLE - Systems and methods for enhancing fluorescent detection of target molecules in a test sample are for use with an irradiating device. First fluorophores are provided for absorption of EMF radiation, and emission of a first signal. Second fluorophores are provided for partial absorption of the first signal, and emission of a second signal distinguishable from the first signal. The fluorophores are combined with the test sample, and secured to the target molecules and relative to one another. After the first fluorophores receive the EMF radiation from the irradiating device, the first signal is detected, together with the second spectral signal if the target molecules are present in the test sample. | 03-03-2011 |
20110070652 | PHAGE MICROARRAY PROFILING OF THE HUMORAL RESPONSE TO DISEASE - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides methods and compositions for phage microarray profiling of cancer (e.g., prostate, lung, or breast cancer). The present invention further provides novel markers useful for the diagnosis, characterization, and treatment of cancers. | 03-24-2011 |
20110097806 | METHOD OF ASSESSING CANCER STATUS IN A BREAST CANCER PATIENT - A method of assessing recurrence status in a breast cancer patient comprises a step of assaying a biological sample from the patient for a level of a biomarker selected from S100β or HOX-C1I, wherein positive detection of one or both of the biomarkers is indicative of a positive recurrence status. Suitably, the method is a method of prognosis of poor disease free survival in a breast cancer patient, wherein positive detection of one or both of the biomarkers is indicative of poor disease survival. The method may also be a method of diagnosis of recurrence, wherein positive detection of circulating S100β is a diagnostic variable of recurrence. The method of diagnosis is carried out on a patient who is undergoing first line therapy and/or a patient who has had surgery to remove a primary breast tumour. | 04-28-2011 |
20110124110 | SYSTEMS AND METHODS FOR BREAST CANCER DETECTION AND RISK ASSESSMENT - The invention relates to a simple screening test for neoplasia, a precancerous condition, or cancer of the breast. A method is described whereby a breast cancer marker is detected in breast fluid. In a particular embodiment, the method involves treating samples of breast fluids with an aldehyde detecting reagent without any prewashing. The appearance in breast fluids of a marker that is detected by an aldehyde detecting reagent, such as a Schiff's reagent, correlates very well with the disease status of the breast cancer subjects from which the fluids were obtained. Screening test kits are also provided. | 05-26-2011 |
20110136240 | DIAGNOSTIC TEST FOR THE DETECTION OF EARLY STAGE LIVER CANCER - The invention provides methods and kits to detect early stage hepatocellular carcinoma or a change in the gradation of hepatocellular carcinoma in mammals. The diagnostic marker is based on the profiling and identification of diagnostic carbohydrates present in a body fluid such as blood serum. | 06-09-2011 |
20120003744 | DIAGNOSTIC METHODS - The present invention provides a method for identifying a biomarker for diagnosis of lymphoma in a canine subject. The method comprises the following steps: (i) providing serum samples from canine subjects with lymphoma (lymphoma samples); (ii) providing serum samples from canine subjects free from lymphoma (control samples); (iii) fractionating the protein components in the serum samples provided in steps (i) and (ii) using anion exchange chromatography; (iv) further purifying proteins from the fractionated samples produced in step (iii) by contacting the proteins therein with a SELDI protein chip comprising a cation exchange surface; (v) characterising the proteins adhered to the cation exchange surface of the SELDI protein chip in step (iv) using mass spectrometry; and (vi) performing a classification and regression tree (CART) analysis to identify proteins capable of acting as biomarkers, either alone or in combination with other proteins. The invention further provides biomarkers for use in the diagnosis of canine lymphoma and methods of diagnosis using the same. | 01-05-2012 |
20120214245 | SYSTEMS AND METHODS FOR BREAST CANCER DETECTION AND RISK ASSESSMENT - The invention relates to a simple screening test for neoplasia, a precancerous condition, or cancer of the breast. A method is described whereby a breast cancer marker is detected in breast fluid. In a particular embodiment, the method involves treating samples of breast fluids with an aldehyde detecting reagent without any prewashing. The appearance in breast fluids of a marker that is detected by an aldehyde detecting reagent, such as a Schiff's reagent, correlates very well with the disease status of the breast cancer subjects from which the fluids were obtained. Screening test kits are also provided. | 08-23-2012 |
20140193919 | METHODS OF DETECTING OVARIAN CANCER - Methods of screening human female subject for a risk of ovarian cancer are described. High levels of calcium in serum are shown to be significantly positively associated with the risk of ovarian cancer and can advantageously be used to triage women into risk categories for more intensive testing. Also included are preoperative methods of determining if an adnexal mass is likely to be malignant or benign. | 07-10-2014 |
20140193920 | METABOLOMICS OF HUMAN BIOLOGICAL FLUIDS IDENTIFY SIGNATURES OF MALIGNANT GLIOMA - A method of identifying a patient in need of therapy to treat a malignant glioma comprising measuring a panel of polar metabolite levels in a biological sample taken from the patient and implementing a therapy to treat the malignant glioma in the patient. | 07-10-2014 |
20140273248 | Application of Ca Isotope Analysis to the Early Detection of Metastatic Cancer - Methods using the application of the Ca isotope method for diagnosing and monitoring the progression of cancers that cause bone loss. The methods also can be used for evaluating cancer treatments, such as aromatase inhibitors and other chemotherapeutic agents, for effects on bone density so that treatment can be modified. | 09-18-2014 |
20150064796 | NONINVASIVE DETECTION OF LUNG CANCER USING EXHALED BREATH - A non-invasive method of detecting or screening for lung cancer in a subject specimen is provided. The method includes detecting elevated levels of one or more carbonyl-containing volatile organic compounds (VOCs) that are biomarkers for lung cancer in exhaled breath from the subject specimen. The method may further include obtaining exhaled breath from the subject specimen; forming adducts of the carbonyl-containing VOCs with a reactive chemical compound; quantifying the adducts of the carbonyl-containing VOCs to establish a subject value for each of the adducts; and comparing each subject value to a threshold healthy specimen value for each of the adducts of the carbonyl-containing VOCs. One or more subject values at quantities greater than threshold healthy specimen values are also useful for screening for lung cancer in the subject specimen. | 03-05-2015 |
20150346225 | METHOD OF DETECTING A RISK OF CANCER - A method of detecting a subject's cancer risk is provided. The method includes: gathering a sample of the subject's body water content via saliva; | 12-03-2015 |
20160041145 | Detection And Quantification Of Acetylamantadine In Urine Samples - A method for quantifying acetylamantadine in a urine sample comprises eluting acetylamantadine from the urine sample using solid phase extraction and quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy. | 02-11-2016 |